Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product

New York (ots/PRNewswire) -

Pfizer Inc said today that a Danish court has granted a
preliminary injunction against Nomeco A/S -- the largest
pharmaceutical wholesaler in Denmark -- that prohibits the sale of a
generic version of Lipitor by generics manufacturer Ranbaxy. The
injunction, issued by the Bailiff's Court of the Copenhagen City
Court in Denmark and subject to possible appeal by Nomeco, requires
Ranbaxy's generic atorvastatin product to be withdrawn from the
Danish market pending the outcome of a patent infringement trial that
has not yet been scheduled.

At issue are three Pfizer patents covering atorvastatin calcium,
the active ingredient in Lipitor, as well as processes and
intermediate compounds used to make atorvastatin. The latest-expiring
of the patents provides coverage for Lipitor through November, 2011.
The Bailiff's Court ruled in Pfizer's favor on all three patents.

"This ruling is another significant milestone in our defense of
Lipitor patents around the world," said Pfizer Senior Vice President
and General Counsel Allen Waxman. "And it's an important outcome for
Pfizer and other medical innovators who invest in high-risk research
to develop life-saving medicines for millions of patients," added
Karin Verland, country manager of Pfizer Denmark.

ots Originaltext: Pfizer Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Bryant Haskins, +1-212-733-8719 / Company News On-Call: Pfizer's
press releases are available through PR Newswire's Company News
On-Call service on PRN's Web Site. Visit
http://www.prnewswire.com/comp/688250.html Photo: A free corporate
logo to accompany this story is available immediately via Wieck Photo
Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions. To retrieve a logo, please call +1-972-392-0888 /
Company News On-Call: http://www.prnewswire.com/comp/688250.html


	hier anmelden...